Advertisement

Association among depression, symptom experience, and quality of life in polycystic ovary syndrome

      Background

      Clinical stigmata of polycystic ovary syndrome include hirsutism, obesity, menstrual disturbances, and infertility. These symptoms impair health-related quality of life. Depression is also common. The relationship among depression, symptom self-perception, and quality of life in polycystic ovary syndrome is poorly understood.

      Objective

      We sought to investigate the relationship between health-related quality of life and depression in women with polycystic ovary syndrome.

      Study Design

      We conducted a secondary analysis of a multicenter, randomized clinical trial (Pregnancy in Polycystic Ovary Syndrome II, NCT00719186) comparing clomiphene citrate vs letrozole in the treatment of infertility. Subjects included 732 women ages 18–40 years with polycystic ovary syndrome by modified Rotterdam criteria. The validated Polycystic Ovary Syndrome Health-Related Quality of Life survey was self-administered, assessing the following domains: emotions, body hair, body weight, menstrual problems, and infertility; scores range from 1–7, with lower numbers indicating poorer quality of life. Depression was evaluated via the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire. Quality-of-life scores were compared between depressed and nondepressed women. Multivariate linear regression models analyzed the association between depression and quality-of-life scores, controlling for age, body mass index, hirsutism score, and duration of infertility.

      Results

      In all, 64 women (8.4%) met criteria for depression. Depressed women reported reduced quality of life in all domains compared to nondepressed women: mood (3.1 vs 4.6, P < .001), body hair (3.5 vs 4.2, P = .002), weight (2.0 vs 3.5, P < .001), menstrual problems (3.3 vs 4.1, P < .001), and infertility (1.9 vs 3.0, P < .001). Global quality-of-life score was reduced in depressed women (2.8 vs 3.9, P < .001). Impairments in quality of life in depressed women persisted in all domains after controlling for objective parameters including age, body mass index, hirsutism score, and infertility duration.

      Conclusion

      Depression is associated with reduced quality of life related to polycystic ovary syndrome symptoms. Disturbances in health-related quality of life in depressed women are not explained by objective measures including body mass index, hirsutism scores, and duration of infertility. Depression may color the experience of polycystic ovary syndrome symptoms and should be considered when there is significant discordance between subjective and objective measures in women with polycystic ovary syndrome.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • March W.A.
        • Moore V.M.
        • Willson K.J.
        • Phillips D.I.
        • Norman R.J.
        • Davies M.J.
        The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.
        Hum Reprod. 2010; 25: 544-551
        • Mehrabian F.
        • Khani B.
        • Kelishadi R.
        • Ghanbari E.
        The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria.
        Endokrynol Pol. 2011; 62: 238-242
        • Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
        Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).
        Hum Reprod. 2004; 19: 41-47
        • Rubin K.H.
        • Glintborg D.
        • Nybo M.
        • Abrahamsen B.
        • Andersen M.
        Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2017; 102: 3848-3857
        • Moran L.J.
        • Misso M.L.
        • Wild R.A.
        • Norman R.J.
        Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.
        Hum Reprod Update. 2010; 16: 347-363
        • Behboudi-Gandevani S.
        • Ramezani Tehrani F.
        • Rostami Dovom M.
        • et al.
        Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies.
        Gynecol Endocrinol. 2016; 32: 343-353
        • Lim S.S.
        • Davies M.J.
        • Norman R.J.
        • Moran L.J.
        Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis.
        Hum Reprod Update. 2012; 18: 618-637
        • Cooney L.G.
        • Lee I.
        • Sammel M.D.
        • Dokras A.
        High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis.
        Hum Reprod. 2017; 32: 1075-1091
        • Dokras A.
        Mood and anxiety disorders in women with PCOS.
        Steroids. 2012; 77: 338-341
        • Veltman-Verhulst S.M.
        • Boivin J.
        • Eijkemans M.J.
        • Fauser B.J.
        Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies.
        Hum Reprod Update. 2012; 18: 638-651
        • Cella D.F.
        Measuring quality of life in palliative care.
        Semin Oncol. 1995; 22: 73-81
        • Barile J.P.
        • Reeve B.B.
        • Smith A.W.
        • et al.
        Monitoring population health for Healthy People 2020: evaluation of the NIH PROMIS(R) Global Health, CDC Healthy Days, and satisfaction with life instruments.
        Qual Life Res. 2013; 22: 1201-1211
        • Barnard L.
        • Ferriday D.
        • Guenther N.
        • Strauss B.
        • Balen A.H.
        • Dye L.
        Quality of life and psychological well-being in polycystic ovary syndrome.
        Hum Reprod. 2007; 22: 2279-2286
        • Coffey S.
        • Bano G.
        • Mason H.D.
        Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36).
        Gynecol Endocrinol. 2006; 22: 80-86
        • Pasch L.
        • He S.Y.
        • Huddleston H.
        • et al.
        Clinician vs self-ratings of hirsutism in patients with polycystic ovarian syndrome: associations with quality of life and depression.
        JAMA Dermatol. 2016; 152: 783-788
        • Bazarganipour F.
        • Ziaei S.
        • Montazeri A.
        • Foroozanfard F.
        • Kazemnejad A.
        • Faghihzadeh S.
        Psychological investigation in patients with polycystic ovary syndrome.
        Health Qual Life Outcomes. 2013; 11: 141
        • Cinar N.
        • Kizilarslanoglu M.C.
        • Harmanci A.
        • et al.
        Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome.
        Hum Reprod. 2011; 26: 3339-3345
        • Himelein M.J.
        • Thatcher S.S.
        Depression and body image among women with polycystic ovary syndrome.
        J Health Psychol. 2006; 11: 613-625
        • Adali E.
        • Yildizhan R.
        • Kurdoglu M.
        • et al.
        The relationship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome.
        J Int Med Res. 2008; 36: 1188-1196
        • Legro R.S.
        • Brzyski R.G.
        • Diamond M.P.
        • et al.
        Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
        N Engl J Med. 2014; 371: 119-129
        • Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
        Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
        Fertil Steril. 2004; 81: 19-25
        • Legro R.S.
        • Brzyski R.G.
        • Diamond M.P.
        • et al.
        Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
        N Engl J Med. 2014; 371: 119-129
        • Hatch R.
        • Rosenfield R.L.
        • Kim M.H.
        • Tredway D.
        Hirsutism: implications, etiology, and management.
        Am J Obstet Gynecol. 1981; 140: 815-830
        • Guyatt G.
        • Weaver B.
        • Cronin L.
        • Dooley J.A.
        • Azziz R.
        Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated.
        J Clin Epidemiol. 2004; 57: 1279-1287
        • Spitzer R.L.
        • Kroenke K.
        • Williams J.B.
        Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.
        JAMA. 1999; 282: 1737-1744
        • Hahn S.R.
        • Kroenke K.
        • Spitzer R.L.
        • Williams J.B.W.
        The PRIME-MD instrument.
        in: Maruish M.E. The use of psychological testing for treatment planning and outcome assessment. 2nd ed. Laurence Erlbaum Associates, Hillsdale (NJ)1999
      1. DHHS. Health-related quality of life and well-being. Washington (DC): US Department of Health and Human Services. Available at: https://www.healthypeople.gov/2020/topics-objectives/topic/health-related-quality-of-life-well-being#2. Accessed January 2018.

        • Cronin L.
        • Guyatt G.
        • Griffith L.
        • et al.
        Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS).
        J Clin Endocrinol Metab. 1998; 83: 1976-1987
        • Nigatu Y.T.
        • Reijneveld S.A.
        • de Jonge P.
        • van Rossum E.
        • Bültmann U.
        The combined effects of obesity, abdominal obesity and major depression/anxiety on health-related quality of life: the lifelines cohort study.
        PLoS One. 2016; 11: e0148871
        • McIntyre R.S.
        • Soczynska J.K.
        • Konarski J.Z.
        • Kennedy S.H.
        The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms.
        Expert Opin Drug Saf. 2006; 5: 157-168
        • Seligman M.E.
        • Maier S.F.
        Failure to escape traumatic shock.
        J Exp Psychol. 1967; 74: 1-9
        • Cuijpers P.
        • Dekker J.
        • Hollon S.D.
        • Andersson G.
        Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis.
        J Clin Psychiatry. 2009; 70: 1219-1229